Compound 60 has an extremely substantial affinity to MDM2 (Ki < one nM), powerful cellular activity, and a very good oral pharmacokinetic profile. Compound sixty is able to attaining full and extended-lasting tumor regression in vivo and is particularly now in section I medical trials for cancer